HIV - Associated lipodystrophy in children

Pediatric Endocrinology Reviews

Volumn 3, Issue 1, 2005, Pages 45-51

  Krause, Jens C ^b   Toye, Mary P ^b   Stechenberg, Barbara W ^b   Reiter, Edward O ^b   Allen, Holley F ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Adipocytokines; Cytokines; HIV; Lipodystrophy; Protease inhibitors

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; FATTY ACID SYNTHASE; FIBRINOGEN; GLUCOCORTICOID; GLUCOSE TRANSPORTER 4; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCORTISONE; INSULIN; INTERLEUKIN 18; INTERLEUKIN 6; LAMIN A; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRASTERONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SOMATOMEDIN BINDING PROTEIN 3; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VPR PROTEIN;

APOPTOSIS; CHILDHOOD DISEASE; CUSHING SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCORTISONE BLOOD LEVEL; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPOATROPHY; LIPOHYPERTROPHY; PATHOPHYSIOLOGY; PHENOTYPE; REVIEW; T LYMPHOCYTE; VIRUS REPLICATION;

ADIPONECTIN; ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CYTOKINES; FIBRINOLYSIS; GLUCOCORTICOIDS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMAN GROWTH HORMONE; HUMANS; LEPTIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 32244442530     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Leonard EG, McComsey GA. Metabolic complications of antiretroviral therapy in children. Pediatr Infect Dis J 2003;22:77-84
2. Yanovski J, Miller K, Kino T, Friedman T, Chrousos G, Tsigos C, Falloon J. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999;84:1925-1931
3. Christeff H, Melchior J, de Truchis P, Perronne C, Nunez E, Gougeon M. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 1999;13:2251-2260
4. Maher B, Lloyd J, Wilkins EGL, Fraser WD, Back D, Park BK, Pirmohamed M. Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters. Antivir Ther 2004;9:879-887
5. Van Rossum A, Gaakeer M, Verweel S, Hartwig N, Wolfs T, Geelen S, Lamberts S, de Groot R. Endocrinologic and immunologic factors associated with recovery of growth in children with human immunodeficiency virus type 1 infection treated with protease inhibitors. Pediatr Infect Dis J 2003;22:70-76
6. Babl F, Regan A, Pelton S. Abnormal body-fat distribution in HIV-1-infected children on antiretrovirals. Lancet 1999;353:1243-1244
7. Jaquet D, Lévine M, Ortega-Rodriguez E, Faye A, Polak M, Vilmer E, Lévy-Marchal C. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000;14:2123-2128
8. Amaya RA, Kozinetz CA, McMeans A, Schwarzwald H, Kline MW. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 2002;21:405-410
9. Bockhorst J, Ksseiry I, Toye M, Chipkin S, Stechenberg B, Fisher D, Allen H. Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors. Pediatr Infect Dis J 2003;22:463-465
10. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004;18:1443-1451
11. Torres AS, Muniz RM, Madero R, Borque C, García-Miyuel M, Gomez MDJ. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 2005;164:271-276
12. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000;22:911-36; discussion 898
13. Jones SP, Janneh O, Back DJ, Pirmohamed M. Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther 2005;10:207-213
14. McComsey G, Bhumbra H, Ma J, Rathore M, Alvarez A. Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study. Pediatrics 2003;111:e275-81
15. Beregszaszi M, Jaquet D, Levine M, Ortega-Rodriguez E, Baltakse V, Polak M, Levy-Marchal C. Severe insulin resistance contrasting with mild anthropometric changes in the adipose tissue of HIV-infected children with lipohypertrophy. Int J Obes Relat Metab Disord 2003;27:25-30
16. Murata H, Hruz P, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251-2054
17. Shalitin S, Phillip M. Role of obesity and leptin in the pubertal process and pubertal growth-a review. Int J Obes Relat Metab Disord 2003;27:869-874
18. Lord G, Matarese G, Howard J, Baker R, Bloom S, Lechler R. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998;394:897-901
19. Motarese G, Castelli-Gattinara G, Cancrini C, Bernardi S, Romiti M, Savarese C, Di Giacomo A, Rossi P, Racioppi L. Serum leptin and CD4+ T lymphocytes in HIV+ children during highly active antiretroviral therapy. Clin Endocrinol (Oxf) 2002;57:643-646
20. Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel R. Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther 2003;8:9-15
21. Vigouroux C, Maachi M, Nguyen T, Coussieu C, Gharakhanian S, Funahashi T, Matsuzawa Y, Shimomura I, Rozenbaum W, Capeau J, Bastard J. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003;17:1503-1511
22. Nogy G, Tsiodras S, Martin L, Avihingsanon A, Gavrila A, Hsu W, Karchmer A, Mantzoros C. Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis 2003;36:795-802
23. Moran SA, Patten N, Young JR, Cochran E, Sebring N, Reynolds J, Premkumar A, Depaoli AM, Skarulis MC, Oral EA, Gorden P. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism 2004;53:513-519
24. Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Garden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 2005;54:1994-2002
25. Weiss R, Dziura J, Burgert T, Tamborlane W, Taksali S, Yeckel C, Allen K, Lopes M, Savoye M, Morrison J, Sherwin R, Caprio S. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350:2362-2374
26. Lihn A, Richelsen B, Pedersen S, Haugaard S, Rathje G, Madsbad S, Andersen O. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003;285:E1072-1080
27. Tong Q, Sankale J, Hadigan C, Tan G, Rosenberg E, Kanki P, Grinspoon S, Hotamisligil G. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab 2003;88:1559-1564
28. Lindegaard B, Keller P, Bruunsgaard H, Gerstoft J, Pedersen B. Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin Exp Immunol 2004;135:273-279
29. Addy C, Gavrila A, Tsiodras S, Brodovicz K, Karchmer A, Mantzoros C. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003;88:627-636
30. Gil P, de Gorgolas M, Estrada V, Arranz A, Rivas P, Yera C, Garcia R, Granizo J, Fernandez-Guerrero M. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load. Clin Infect Dis 2004;39:1024-1029
31. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman M, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001;7:941-946
32. Xu A, Yin S, Wong L, Chan K, Lam K. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 2004;145:487-494
33. Riddle T, Fichtenbaum C, Hui D. Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice. J Acquir Immune Defic Syndr 2003;33:564-570
34. Nadal D, Steiner F, Cheseaux J, Rudin C. Ritonavir promotes increased growth in HIV-infected children. Paediatric AIDS Group of Switzerland. AIDS 1998;12:2356-2357
35. Verweel G, van Rossum A, Hartwig N, Wolfs T, Scherpbier H, de Groot R. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth. Pediatrics 2002;109:E25
36. Nachman SA, Lindsey JC, Moye J, Stanley KE, Johnson GM, Krogstad PA, Wiznia AA, Team PACTGS. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2005;24:352-357
37. Watson DC, Counts DR. Growth hormone deficiency in HIV-infected children following successful treatment with highly active antiretroviral therapy. J Pediatr 2004;145:549-551
38. Panamonta O, Kosalaraksa P, Thinkhamrop B, Kirdpon W, Ingchanin C, Lumbiganon P. Endocrine function in Thai children infected with human immunodeficiency virus. J Pediatr Endocrinol Metab 2004;17:33-40
39. Vigano A, Mora S, Brambilla P, Schneider L, Merlo M, Monti L, Manzoni P. Impaired growth hormone secretion correlates with visceral adiposity in highly active antiretroviral treated HIV-infected adolescents. AIDS 2003;17:1435-1441
40. Koutkia P, Canavan B, Breu J, Grinspoon S. Growth Hormone Responses to GHRH-Arginine Testing in HIV Lipodystrophy. J Clin Endocrinol Metab 2005;90:32-38
41. Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA 2004;292:210-218
42. Haugaard SB, Andersen O, Hansen BR, Orskov H, Andersen UB, Madsbad S, Iversen J, Flyvbjerg A. Insulin-like growth factors, insulin-like growth factor-binding proteins, insulin-like growth factor-binding protein-3 protease, and growth hormone-binding protein in lipodystrophic human immunodeficiency virus-infected patients. Metabolism 2004;53:1565-1573
43. Burgess E, Wanke C. Use of recombinant human growth hormone in HIV-associated lipodystrophy. Curr Opin Infect Dis 2005;18:17-24
44. Viganò A, Mora S, Manzoni P, Schneider L, Beretta S, Molinaro M, di Natale B, Brambilla P. Effects of recombinant growth hormone on visceral fat accumulation: pilot study in human immunodeficiency virus-infected adolescents. J Clin Endocrinol Metab. 2005;90:4075-4080
45. Sutinen J, Kannisto K, Korsheninnikova E, Nyman T, Ehrenborg E, Andrew R, Wake D, Hamsten A, Walker B, Yki-Jarvinen H. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 2004;47:1668-1671
46. Christeff N, De Truchis P, Melchior J, Perronne C, Gougeon M. Longitudinal evolution of HIV-1-associated lipodystrophy is correlated to serum cortisol:DHEA ratio and IFN-alpha. Eur J Clin Invest 2002;32:775-784
47. Kino T, Chrousos G. Human immunodeficiency virus type-1 accessory protein Vpr: a causative agent of the AIDS-related insulin resistance/lipodystrophy syndrome? Ann N Y Acad Sci 2004;1024:153-167
48. Kim J, Sarraf P, Wright M, Yao K, Mueller E, Solanes G, Lowell B, Spiegelman B. Nutritional and insulin regulation of fatty acid synthetase and leptin gene expression through ADD1/SREBP1. J Clin Invest 1998;101:1-9
49. Dowell P, Flexner C, Kwiterovich P, Lane M. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 2000;275:41325-4132
50. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001;50:1378-1388
51. Caron M, Auclair M, Sterlingot H, Kornprobst M, Copeau J. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003;17:2437-2444
52. Bastard J, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, Luboinski J, Laville M, Maachi M, Girard P, Rozenbaum W, Levan P, Capeau J. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002;359:1026-1031
53. Hadri K, Glorian M, Monsempes C, Dieudonne M, Pecquery R, Giudicelli Y, Andreani M, Dugail I, Feve B. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J Biol Chem 2004;279:15130-15141
54. Miserez A, Muller P, Barella L, Schwietert M, Erb P, Vernazza P, Battegay M. A single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-related hyperlipoproteinaemia. AIDS 2001;15:2045-2049
55. Yang A, King M, Han L, Isaacson J, Mueller T, Grimm D, Scott C, Katz D. Lack of correlation between SREBF1 genotype and hyperlipidemia in individuals treated with highly active antiretroviral therapy. AIDS 2003;17:2142-2143
56. Lloyd DJ, Trembath RC, Shackleton S. A novel interaction between lamin A and SREBP1: implications for partial lipodystrophy and other laminopathies. Hum Mol Genet 2002;11:769-777
57. Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Jarvinen A, Ristola M, Yki-Järvinen H. Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study. Antivir Ther 2003;8:199-207
58. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S, Cooper DA, investigators R. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004;363:429-438
59. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 2004;140:786-794
60. Hotamisligil G, Murray D, Choy L, Spiegelman B. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc Natl Acad Sci USA 1994;91:4854-4858
61. Christeff N, Melchior J, de Truchis P, Perronne C, Gougeon M. Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome. Eur J Clin Invest 2002;32:43-50
62. Maher B, Alfirevic A, Vilar FJ, Wilkins EGL, Park BK, Pirmohamed M. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 2002;16:2013-2018
63. Young E, Considine R, Sattler F, Deeg M, Buchanan T, Degawa-Yamauchi M, Shankar S, Edmondson-Melancon H, Hernandez J, Dube M. Changes in thrombolytic and inflammatory markers after initiation of indinavir- or amprenavir-based antiretroviral therapy. Cardiovasc Toxicol 2004;4:179-168
64. Mynarcik D, McNurlan M, Steigbigel R, Fuhrer J, Gelato M. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000;25:312-321
65. Johnson J, Albu J, Engelson E, Fried S, Inada Y, Ionescu G, Kotler D. Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 2004;286: E261-271
66. Reddy P. Interleukin-18: recent advances. Curr Opin Hematol 2004;11:405-410
67. Torre D, Speranza F, Martegani R, Pugliese A, Castelli F, Basilico C, Biondi G. Circulating levels of IL-18 in adult and paediatric patients with HIV-1 infection. AIDS 2000;14:2211-2212
68. Shapiro L, Puren A, Barton H, Novick D, Peskind R, Shenkar R, Gu Y, Su M, Dinarello C. Interleukin 18 stimulates HIV type 1 in monocytic cells. Proc Natl Acad Sci U S A 1998;95:12550-1255
69. Lindegaard B, Hansen A, Gerstoft J, Pedersen B. High Plasma Level of Interleukin-18 in HIV-Infected Subjects With Lipodystrophy. J Acquir Immune Defic Syndr 2004;36:588-593
70. Lindegaard B, Hansen A, Pilegaard H, Keller P, Gerstoft J, Pedersen B. Adipose tissue expression of IL-18 and HIV-associated lipodystrophy. AIDS 2004;18:1956-1958
71. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003;52:2784-2789
72. Memon R, Feingold K, Moser A, Doerrler W, Grunfeld C. In vivo effects of interferon-alpha and interferon-gamma on lipolysis and ketogenesis. Endocrinology 1992;131:1695-1702
73. Hadigan C, Meigs J, Rabe J, D'Agostino R, Wilson P, Lipinska I, Tofler G, Grinspoon S. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001;86:939-943
74. De Larranaga G, Galich A, Puga L, Alonso B, Benetucci J. Insulin resistance status is an important determinant of PAI-1 levels in HIV-infected patients, independently of the lipid profile. J Thromb Haemost 2004;2:532-534
75. Koppel K, Bratt G, Schulman S, Bylund H, Sandstrom E. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002;29:441-449
76. Rusnati M, Coltrini D, Campioni D, Tanghetti E, Corallini A, Barbanti-Brodano G, Giuliani R, Gibellini D, Presta M. Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice. AIDS 1997;11:727-736
77. Wolf K, Tsakiris D, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis 2002;185:456-462